Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study Evaluated Efficacy and Safety of CD19/22 Chimeric Antigen Receptor T Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT04539444 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Soochow University as lead sponsor.

NCT NCT04539444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04539444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study Evaluated Efficacy and Safety of CD19/22 Chimeric Antigen Receptor T Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Lead sponsor
The First Affiliated Hospital of Soochow University
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2020
Completion date
March 31, 2023
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory non-hodgkin lymphoma, relapsed non hodgkin lymphoma